Flash FinanceUS
Market closed · weekend S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · Phibro Animal Health (PAHC)

Phibro Animal Health: President of North America Region Rob Aukerman to retire Dec. 31

Neutral Impact 3 of 5 leadership Written later

Phibro Animal Health disclosed that Rob Aukerman will retire as President, North America Region, effective December 31, 2024, and will stay on in an advisory role until June 30, 2025. Todd Armstrong, currently Vice President of the US Ruminant Business, will succeed him as President, North American Region, effective January 1, 2025. The filing describes a planned transition rather than a financial change.

Key points

  • Rob Aukerman notified the company on November 7, 2024 that he will retire effective December 31, 2024
  • Aukerman will continue in an advisory capacity until June 30, 2025
  • Todd Armstrong, Vice President of the US Ruminant Business since 2020, will be promoted to President, North American Region, effective January 1, 2025

The filing

CompanyPhibro Animal Health (PAHC)
Form8-K, current report
Filed with the SECNov 12, 2024, 4:15 PM ET
Accession number0001104659-24-116790

Items reported: 5.02 Director / Officer Change

Read the filing on SEC.gov ↗

Written by AI (Anthropic Claude, claude-haiku-5-5) on Nov 8, 2026, 6:58 AM ET, from the text of the filing and its press-release exhibits only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on November 12, 2024.

Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.